Catalent (CTLT) Downgraded by Zacks Investment Research

Catalent (NYSE:CTLT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Zacks.com reports.

According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “

Several other brokerages have also recently issued reports on CTLT. Jefferies Financial Group boosted their price objective on Catalent from $44.00 to $50.00 and gave the company a “hold” rating in a report on Tuesday, April 16th. Morgan Stanley boosted their price objective on Catalent from $46.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, April 16th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. First Analysis reissued an “outperform” rating and issued a $49.00 price objective on shares of Catalent in a report on Tuesday, March 5th. Finally, TheStreet raised Catalent from a “c” rating to a “b-” rating in a report on Wednesday, February 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $49.57.

Shares of CTLT stock opened at $45.21 on Wednesday. The stock has a market capitalization of $6.56 billion, a PE ratio of 28.43, a P/E/G ratio of 2.41 and a beta of 1.70. The company has a quick ratio of 1.63, a current ratio of 2.08 and a debt-to-equity ratio of 1.36. Catalent has a 52-week low of $29.23 and a 52-week high of $47.04.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.07. The business had revenue of $617.50 million during the quarter, compared to analysts’ expectations of $644.88 million. Catalent had a return on equity of 17.42% and a net margin of 5.48%. The company’s revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.41 EPS. As a group, equities research analysts expect that Catalent will post 1.69 earnings per share for the current fiscal year.

In related news, insider Aristippos Gennadios sold 3,392 shares of Catalent stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $42.18, for a total value of $143,074.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP William Downie sold 7,315 shares of Catalent stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $42.00, for a total value of $307,230.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,326 shares of company stock valued at $2,303,676. 1.40% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in CTLT. Janus Henderson Group PLC increased its stake in shares of Catalent by 17.6% in the 1st quarter. Janus Henderson Group PLC now owns 17,503,223 shares of the company’s stock valued at $710,456,000 after purchasing an additional 2,620,352 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Catalent by 29.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock worth $363,316,000 after buying an additional 1,819,020 shares in the last quarter. Oregon Public Employees Retirement Fund increased its stake in Catalent by 3,074.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,798,868 shares of the company’s stock worth $58,000 after buying an additional 1,742,199 shares in the last quarter. Norges Bank purchased a new stake in Catalent during the 4th quarter worth approximately $47,177,000. Finally, Vanguard Group Inc increased its stake in Catalent by 9.4% during the 3rd quarter. Vanguard Group Inc now owns 12,925,639 shares of the company’s stock worth $588,763,000 after buying an additional 1,110,779 shares in the last quarter. Hedge funds and other institutional investors own 96.85% of the company’s stock.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

See Also: What is Forex?

Get a free copy of the Zacks research report on Catalent (CTLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.